Therapeutic Efficacy in Combined Administration of Repaglinide plus Metformin for Treatment of the Obese Patients with NIDDM

ObjectivesTo explore the therapeutic efficacy in combined administration of repaglinide plus metformin for treatment of the obese patients with NIDDM.MethodsSixty obese patients with NIDDM whose blood glucose levels had not been controlled after treating singly with metformin for two months were randomly divided into three groups: ①Combined administration of metformin plus repaglinide;② metformin plus glibizide, or ③ using placebo.They were scheduled for three months, respectively. Changes in criteria such as blood levels of glucose and lipids, body weight(Wt)and hypoglycemic response were followed up before and after the treatment.Results①In group of metformin plus repaglinide ,fasting blood glucose(FBG),2h post meal glucose(2hPG),glycosylated HbAIC(GHbAIC),TG,VLDL and Wt all decreased significantly after treatment as compared with the results before treatment(P0.05);whereas in group of metformin plus glibizide ,there were significant differences in FBG,2hPG and GHbAIC following therapy(P0.01);but no obvious changes of TG,VLDL and Wt were observed (P0.05).②The rate of hypoglycemic response in group② increased more significantly than in group①[45% vs 15%,χ 2=4.28,P0.05].ConclusionCombined administration of repaglinide plus metformin in obese patients with NIDDM whose blood glucose levels have not been controlled by single metformin therapy reveals good therapeutic efficacy, with lowering of FBG, control of blood lipids levels and decrease in Wt. It is a reliable measure of safety.